

Acta Medica Okayama

Volume 40, *Issue* 3

1986

Article 7

JUNE 1996

Detection of type V collagen-degrading enzyme activity in human liver.

Michio Kobayashi*	Harushige Nakatsukasa [†]	Akiharu Watanabe [‡]
Yasuhiko Yamauchi**	Masachika Fujiwara ^{††}	Makoto Hashimoto ^{‡‡}
Masatomo Watanabe [§]	Toshihiro Higashi [¶]	Hideo Nagashima

*Okayama University,

[†]Okayama University,

[‡]Okayama University,

**Okayama University,

^{††}Okayama University,

^{‡‡}Okayama University,

[§]Okayama University,

[¶]Okayama University,

^{||}Okayama University,

Detection of type V collagen-degrading enzyme activity in human liver.*

Michio Kobayashi, Harushige Nakatsukasa, Akiharu Watanabe, Yasuhiko Yamauchi, Masachika Fujiwara, Makoto Hashimoto, Masatomo Watanabe, Toshihiro Higashi, and Hideo Nagashima

Abstract

Type V collagen-degrading enzyme activity was detected as a metalloprotease acting at neutral pH in the human liver. Type V collagen extracted from human placenta and labeled with [1-¹⁴C] acetic anhydride was used as the substrate in the assay. Four major degradation products with relatively high molecular weights were observed upon polyacrylamide gel electrophoresis of the incubation mixture of type V collagen and liver homogenate. The significance of the measurement of this enzyme activity was discussed in relation to the clarification of the mechanism of liver fibrosis.

KEYWORDS: type V collagen-degrading enzyme activity, human liver, liver fibrosis, collagen degradation products

*PMID: 3017052 [PubMed - indexed for MEDLINE]

Detection of Type V Collagen-Degrading Enzyme Activity in Human Liver

Michio Kobayashi, Harushige Nakatsukasa, Akiharu Watanabe, Yasuhiko Yamauchi, Masachika Fujiwara, Makoto Hashimoto, Masatomo Watanabe, Toshihiro Higashi, and Hideo Nagashima

The First Department of Internal Medicine, Okayama University Medical School, Okayama 700, Japan

Type V collagen-degrading enzyme activity was detected as a metalloprotease acting at neutral pH in the human liver. Type V collagen extracted from human placenta and labeled with [^{14}C] acetic anhydride was used as the substrate in the assay. Four major degradation products with relatively high molecular weights were observed upon polyacrylamide gel electrophoresis of the incubation mixture of type V collagen and liver homogenate. The significance of the measurement of this enzyme activity was discussed in relation to the clarification of the mechanism of liver fibrosis.

Key words : type V collagen-degrading enzyme activity, human liver, liver fibrosis, collagen degradation products

Liver fibrosis is a pathological state of collagen deposition in the liver. Recent studies (1, 2) have demonstrated the presence of type IV and V collagens (approximately one-third of the total collagen content) as well as type I and III collagens (two-thirds) in normal liver. In the fibrotic liver, the levels of these types of collagen are high (1). However, type IV and V collagens may play a role different from that of interstitial (type I and III) collagen. Collagen accumulation results from increased production and/or decreased degradation of collagen. However, the mechanism of type IV and V collagen degradation in the fibrotic liver is not known.

Vertebrate collagenase (EC 3. 4. 24. 7) degrades type I and III collagens at a specific site, but does not act on type IV and V collagens. The presence of type V collagen-degrading enzyme has been reported in media

from cultured murine reticulum cell sarcoma (3), human leiomyosarcoma (3) and rabbit pulmonary alveolar macrophages (4), and in sputum from patients with chronic obstructive pulmonary disease (5). However, this enzyme has not been detected in the liver. The present paper describes the detection of type V collagen-degrading enzyme activity in the human liver.

Type V collagen was extracted from the placenta using pepsin at an enzyme/substrate ratio of 1 : 400 by weight for 24 h (6). NaCl precipitation at acidic and neutral pHs (pH 2.8 and 7.5, respectively) was performed on the supernatant of the digest. Type V collagen thus purified was labeled with [^{14}C] acetic anhydride (New England Nuclear) (7). The labeled collagen was stored at -70°C until use. All procedures were done at 4°C , unless otherwise indicated.

The human liver, obtained by autopsy of

patients within 9 h of death, was homogenized with 4 volumes of 50 mM Tris-HCl buffer (pH 7.5) containing 5 mM CaCl_2 , 200 mM NaCl and 0.1% Triton X-100 using a Polytron homogenizer at a speed of 18,000 rpm for 2 min. Type V collagen-degrading activity was measured by the method of Liotta *et al.* (3) with some modifications: The liver homogenate was preincubated with 1 mM 4-aminophenylmercuric acetate (APMA) at 37°C for 1 h to activate the enzyme. Then, 160 μg of [$1\text{-}^{14}\text{C}$] type V collagen (124 dpm/ μg collagen) was incubated at 37°C for 1 h with 8 μl of the liver homogenate in a final volume of 650 μl of 50 mM Tris-HCl buffer (pH 7.5) containing 5 mM CaCl_2 , 200 mM NaCl and 1 mM diisopropyl fluorophosphate (DFP, Sigma). Control tubes contained 10 mM ethylenediamine tetraacetic acid (EDTA) which inhibits the enzyme. The reaction was terminated by adding trichloroacetic acid (final 2%) and tannic acid (0.1%) with bovine serum albumin (20 μg) as a precipitation carrier. After standing at 4°C for 30 min, each tube was centrifuged at 3,000 rpm for 30 min and radioactivity of the supernatant was determined with a liquid scintillation counter (Aloka LSC-700). Each assay was run in duplicate.

Type V collagen and its degradation prod-

ucts were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) (8) and PAGE (9).

Purified type V collagen showed 2 bands





Fig. 1 SDS-PAGE (7.5% gel) patterns of type I and type V collagens. Untreated collagens (20 μg each) purified from human placenta were applied: Lane 1, type I collagen; lane 2, type V collagen.

Fig. 2 Effect of the amount of liver homogenate and the reaction time on type V collagen-degrading enzyme activity.






Fig. 3 PAGE (7.5% gel) patterns of type V collagen treated with human liver homogenate. Purified type V collagen (40 μ g) was incubated with 10 μ l of liver homogenate in the presence of 1 mM diisopropyl fluorophosphate at 37°C. Lane 1, type V collagen alone; lane 2, type V collagen+homogenate for 2 h; lane 3, type V collagen+homogenate for 6 h; lane 4, type V collagen+homogenate for 24 h; lane 5, type V collagen+homogenate in the presence of EDTA for 24 h.

on SDS-PAGE, which corresponded to α_1 (V) and α_2 (V) (Fig. 1). Type V collagen-degrading enzyme activity was maximally activated when the liver homogenate was preincubated with 1 mM APMA for 1 h. Trypsin also activated the enzyme activity, but not as much as APMA. The velocity of the reaction was proportional to the amount of the homogenate up to 12 μ l and to the reaction time up to 60 min (Fig. 2). The degradation products were examined by PAGE (Fig. 3). Four major degradation products with relatively large molecular weights were seen after 2 h of the incubation of type V collagen with liver homogenate. Two smaller degradation products appeared 6 h after the start of the incubation; further degradation was observed after 24 h. The degradation

was completely inhibited by the addition of EDTA as shown in lane 5 of Fig. 3.

Type V collagen-degrading enzyme activity was detected in the human liver. The enzyme was active at neutral pH. The enzyme activity was inhibited by EDTA, indicating that this enzyme is a metalloprotease. Prior activation of this enzyme with APMA was necessary for the measurement of the activity in the liver homogenate, suggesting that the enzyme is present as an enzyme-inhibitor complex *in vivo* (10). Degradation products with relatively large molecular weights, observed after 2 h of the incubation, were similar to those produced by the enzyme in cultured rabbit macrophages (4) or human sputum (5).

Type V collagen was increased in the

sinusoidal area and portal tract in the cirrhotic liver (2). Furthermore, remarkable accumulation of type V collagen started at the early stage of liver cirrhosis (11). However, no study of the degradation of type V collagen in the liver has been reported. In the present study, type V collagen-degrading enzyme activity was detected in the human liver. Measurement of this enzyme activity in various stages of fibrosis may contribute to the clarification of the mechanism of liver fibrosis. The assay method described herein will be useful because the activity can be determined with a small amount of biopsied liver.

References

1. Rojkind M, Giambrone M-A and Biempica L: Collagen types in normal and cirrhotic liver. *Gastroenterology* (1979) **76**, 710-719.
2. Biempica L, Morecki R, Wu CH, Giambrone M-A and Rojkind M: Immunocytochemical localization of type B collagen. *Am J Pathol* (1980) **98**, 591-602.
3. Liotta LA, Lanzer WL and Garbisa S: Identification of a type V collagenolytic enzyme. *Biochem Biophys Res Commun* (1981) **98**, 184-190.
4. Mainardi CL, Seyer JM and Kang AH: Type-specific collagenolysis: A type V collagen-degrading enzyme from macrophages. *Biochem Biophys Res Commun* (1980) **97**, 1108-1115.
5. Rich EA, Seyer JS, Kang AH and Mainardi CL: Identification of a type V collagen-degrading enzyme from human sputum. *Am Rev Respir Dis* (1983) **128**, 166-169.
6. Sage H, Woodbury RG and Bornstein P: Structural studies on human type IV collagen. *J Biol Chem* (1979) **254**, 9893-9900.
7. Cawston TE and Barrett AJ: A rapid and reproducible assay for collagenase using [1-¹⁴C] acetylated collagen. *Anal Biochem* (1979) **99**, 340-345.
8. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* (1970) **227**, 680-685.
9. Nagai Y, Gross J and Piez KA: Disc electrophoresis of collagen components. *Ann NY Acad Sci* (1964) **121**, 494-500.
10. Sellers A, Cartwright E, Murphy G and Reynolds JJ: Evidence that latent collagenases are enzyme-inhibitor complexes. *Biochem J* (1977) **163**, 303-307.
11. Murata K, Kudo M, Onuma F and Motoyama T: Changes of collagen types at various stages of human liver cirrhosis. *Hepato-gastroenterol* (1984) **31**, 158-161.

Received: January 14, 1986

Accepted: April 11, 1986

Reprint requests to:

Michio Kobayashi

The First Department of Internal Medicine

Okayama University Medical School

2-5-1 Shikata-cho

Okayama 700, Japan